Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

Summary

The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.

Timeline

Start

2019-08-26

Primary completion

2021-02-05

Completion

2021-05-26

Publications

• Erdmann N, Williams WB, Walsh SR, Cain DW, Clark M, Tuck R, Holmes S, Clardy B, Foulger A, Parks R, Barr M, Eaton A, Saunders KO, Grunenberg N, Edlefsen P, Goepfert PA, Cohen KW, Maenza J, Mayer K, Van Tieu H, Sobieszczyk ME, Swann E, Lu H, De Rosa SC, Sagawa ZK, Lin BC, Carrol RE, McKee K, Doria-Rose NA, Louder MK, Moody MA, Fox CB, Ferrari G, Edwards RJ, Acharya P, Alam SM, Tomaras GD, Montefiori DC, Gilbert PB, McElrath MJ, Corey L, Haynes BF, Baden LR; NIAID HVTN 133 Study Group. An HIV-1 gp41 peptide-liposome vaccine elicits neutralizing epitope-targeted antibody responses in healthy individuals. medRxiv [Preprint]. 2025 Aug 22:2024.03.15.24304305. doi: 10.1101/2024.03.15.24304305.

Drugs

Indications